Digoxin Use in Cardiac Amyloidosis
With limited options for rate control of atrial fibrillation in the setting of low-output heart failure (HF), digoxin may appear to be a reasonable option for patients with cardiac amyloidosis (CA). However, current guidelines, based on historical case reports and an in vitro study, state that digoxin should generally be avoided in CA due to increased sensitivity for digoxin toxicity. A recent study of 107 patients with AL amyloidosis given digoxin showed relative safety with cautious use, with 11% of patients developing significant arrhythmias.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Joseph P. Donnelly, Andrej Gabrovsek, Brett W. Sperry, Laura Young, Jerry Estep, W.H. Wilson Tang, Mazen Hanna Tags: 059 Source Type: research
More News: Amyloidosis | Arrhythmia | Atrial Fibrillation | Cardiology | Heart | Heart Failure | History of Medicine | Study | Toxicology